NLS Pharmaceutics AG NLSP
Set alert
As of Dec 12, 9:30 AM ET
- YTD
- -86.21%
- 1 year
- -92.46%
- Open
- 3.31
- Prev close
- 2.91
- Mkt cap
- 4.69M
- Vol
- 113.99K
- Avg vol
- 380.73K
- EPS
- -6.74
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.91
- High
- 3.51
- Forward P/E
- -3.60
- Beta
- -0.52
- Short ratio
- 0.15
- Inst. own
- 19.40%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 21, 2024
- 50-d avg
- 3.46
- 200-d avg
- 5.96
- 1y target
- 0.00
News
12 months ago prnewswire.com
NewcelX Provides Business and Strategic Roadmap Update Following Closing of Merger with NLS Pharmaceutics Ltd.
ZURICH , Nov. 3, 2025 /PRNewswire/ -- NewcelX Ltd. (Nasdaq: NCEL) ("NewcelX" or the "Company"), a Swiss clinical-stage biopharmaceutical company developing cell-based and small-molecule therapies for…
1 year ago prnewswire.com
NLS Pharmaceutics Ltd. and Kadimastem Ltd.
Combined Company Re-Named NewcelX Ltd., to Commence Trading on the Nasdaq Capital Market on October 31, 2025 under the Ticker Symbol "NCEL" ZURICH and NESS ZIONA, Israel , Oct. 30, 2025 /PRNewswire/…
1 year ago prnewswire.com
NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs
DOXA Platform Expansion Strengthens Cognitive, Arousal, and Neuroprotective Programs Supported by Solid Cash Position and Strategic Funding Outlook ZURICH , Oct. 30, 2025 /PRNewswire/ -- NLS…
1 year ago prnewswire.com
NLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following Merger
ZURICH , Oct. 29, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) ("NLS" or the "Company"), a biopharmaceutical company focused on developing innovative therapies for central nervous…
1 year ago prnewswire.com
NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem
ZURICH , Oct. 29, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and…
1 year ago prnewswire.com
NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares
ZURICH and NESS ZIONA, Israel , Oct. 29, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company") and Kadimastem Ltd.
1 year ago prnewswire.com
NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies
The collaboration will progress under the combined company, NewCelX, upon completion of the anticipated merger ZURICH and NESS ZIONA, Israel , Oct. 27, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd.…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
1 year ago prnewswire.com
NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025
ZURICH , Oct. 23, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) (Nasdaq: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on central nervous…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
1 year ago prnewswire.com
NLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General Meeting
Vote clears final corporate milestone, paving the way for the closing of the merger and the combined company of NewCelX Ltd., a Nasdaq-listed biotechnology company ZURICH , Sept.
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers bioAffinity Technologies (NASDAQ: BIAF) stock increased by 71.8% to $5.86 during Friday's pre-market session. The company's market cap stands at $4.5 million.
1 year ago prnewswire.com
Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger
ZURICH and NESS ZIONA, Israel , Sept. 10, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd.
1 year ago prnewswire.com
NLS Pharmaceutics and Kadimastem announce a Hong Kong Patent Covering Cell-Selection and Enrichment Technology for IsletRx for Diabetes Patients
Patent grant broadens IP protection in Asia and complements prior patents in Europe, the United States and India Hong Kong represents a meaningful diabetes market and a critical gateway into Mainland…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
1 year ago prnewswire.com
NLS Pharmaceutics Highlights Continued Progress in iTOL-102 Diabetes Program as BIRD Foundation Approves Additional Milestone Payment to Kadimastem and iTolerance for Continued Co-Development of Type 1 Diabetes Cell Therapy
Approval Follows Successful Pre-IND Meeting with the U.S. FDA on iTOL-102, a Potential Cure for Type 1 diabetes that would circumvent the need for life-long immunosuppression drugs ZURICH , July 17,…
1 year ago benzinga.com
Why Greenbrier Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
Shares of The Greenbrier Companies, Inc. (NYSE: GBX) rose sharply in today's pre-market trading after the company posted stronger-than-expected results for the third quarter. The company posted…
1 year ago prnewswire.com
NLS Pharmaceutics and Kadimastem Announce Pricing and Closing of $1 Million Equity Financing
Accumulated proceeds of $3 million including the initial closing held in March 2025 ZÜRICH, June 30, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd . (NASDAQ: NLSP) ("NLS" or the "Company"), a Swiss…
1 year ago prnewswire.com
NLS Pharmaceutics CEO Issues Letter to Shareholders
ZURICH , June 16, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system…
1 year ago prnewswire.com
NLS Pharmaceutics to Present New Data on the Dual Efficacy of Mazindol ER in Fentanyl Reward and Withdrawal at the 2025 ASCP Annual Meeting
ZURICH , May 21, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd . (NASDAQ: NLSP), a Swiss clinical-stage biopharmaceutical company focused on central nervous system ("CNS") disorders, announces that it…
1 year ago prnewswire.com
NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models
Non-opioid, multi-mechanism profile positions Mazindol as a differentiated asset in addiction therapeutics Favorable results support potential expansion into high-value markets beyond ADHD and…
1 year ago accessnewswire.com
NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement
The equity financing is at a 10% premium to the market share price1 ZÜRICH, SWITZERLAND / ACCESS Newswire / March 31, 2025 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP) ("NLS" or the "Company"), a Swiss…
1 year ago prnewswire.com
NLS Pharmaceutics CEO Issues Letter to Shareholders
ZURICH , March 10, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system…
1 year ago prnewswire.com
NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform
ZÜRICH, Switzerland , Feb. 27, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) (Nasdaq: NLSPW) ("NLS" or the "Company"), in collaboration with Aexon Labs Inc. ("Aexon Labs"), is pleased to…
1 year ago prnewswire.com
Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment
Companies Advance Collaborative Clinical Development of iTOL-102: A Potential Cure for Diabetes Without the Need for Chronic Life-long Immune Suppression ZURICH and NESS ZIONA, Israel , Feb. 25, 2025…
-
2 years ago benzinga.com
Why Vuzix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Why Vuzix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
-
2 years ago benzinga.com
Why Quantum Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Why Quantum Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
-
3 years ago benzinga.com
Benzinga's Top Ratings Upgrades, Downgrades For September 14, 2023
Benzinga's Top Ratings Upgrades, Downgrades For September 14, 2023
-
3 years ago benzinga.com
Why Coupa Software Shares Jumped Around 29%; Here Are 72 Biggest Movers From Wednesday
Gainers Kalera Public Limited Company (NASDAQ: KAL) jumped 76.9% to close at $0.1610 on Wednesday after gaining 9% on Tuesday. Kalera recently posted a Q3 loss of $0.05 per share.
-
4 years ago benzinga.com
Why Laser Photonics Shares Jumped By Around 44%; Here Are 72 Biggest Movers From Yesterday
Gainers FedNat Holding Company (NASDAQ: FNHC) shares climbed 107.7% to close at $0.3395 on Tuesday.
-
4 years ago benzinga.com
Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday
Gainers Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX…
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 120 companies achieved new lows for the year.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
On Monday, 100 companies reached new 52-week lows.
-
4 years ago benzinga.com
This Healthcare Stock Jumped 110%; Here Are 64 Biggest Movers From Yesterday
Gainers Virax Biolabs Group Limited (NASDAQ: VRAX) shares climbed 264% to close at $18.20 on Thursday. The company offered shares at an expected price of $5.00 per share with an insider lock-up…
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday, 1043 companies hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
Tuesday morning saw 454 companies set new 52-week lows.
-
4 years ago benzinga.com
58 Biggest Movers From Yesterday
Gainers Eargo, Inc. (NASDAQ: EAR) shares climbed 59.7% to close at $7.28 on Thurs after the company announced the Department of Justice confirmed to it that the previously-announced criminal probe is…
-
4 years ago benzinga.com
45 Biggest Movers From Yesterday
Gainers ATA Creativity Global (NASDAQ: AACG) gained 114.3% to close at $2.55.
-
5 years ago benzinga.com
82 Biggest Movers From Yesterday
Gainers Five Prime Therapeutics, Inc. (NASDAQ: FPRX) shares surged 78.7% to close at $38.00 on Thursday after Amgen announced plans to acquire the company for $1.9 billion.